Qiagen (NYSE:QGEN) Cut to “Hold” at Wall Street Zen

Qiagen (NYSE:QGEN) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research analysts have also weighed in on the stock. Robert W. Baird set a $53.00 price target on shares of Qiagen in a research note on Friday, February 6th. TD Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Jefferies Financial Group reissued a “buy” rating and set a $59.00 target price on shares of Qiagen in a report on Thursday, February 5th. UBS Group set a $52.00 price target on Qiagen in a research note on Monday, February 9th. Finally, Stifel Nicolaus set a $50.00 price objective on Qiagen and gave the company a “hold” rating in a research note on Friday, February 6th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $55.20.

Qiagen Price Performance

Qiagen stock opened at $39.06 on Friday. The stock has a market capitalization of $8.05 billion, a P/E ratio of 19.37, a P/E/G ratio of 1.94 and a beta of 0.70. The company’s fifty day moving average price is $47.70 and its 200 day moving average price is $48.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. Qiagen has a 1 year low of $38.79 and a 1 year high of $57.81.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The company had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.61 earnings per share. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, equities research analysts anticipate that Qiagen will post 2.26 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Several large investors have recently added to or reduced their stakes in QGEN. United Services Automobile Association acquired a new position in shares of Qiagen during the 1st quarter valued at about $239,000. Cetera Investment Advisers increased its position in Qiagen by 23.9% during the second quarter. Cetera Investment Advisers now owns 17,239 shares of the company’s stock worth $827,000 after purchasing an additional 3,322 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Qiagen by 117.0% during the second quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock worth $60,217,000 after purchasing an additional 675,498 shares during the period. MAI Capital Management raised its stake in Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Qiagen by 2.7% in the 2nd quarter. Rhumbline Advisers now owns 199,503 shares of the company’s stock valued at $9,588,000 after purchasing an additional 5,200 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.